Our Pipeline
Our unique IND engine has helped us identify novel pathways and targets in immuno-oncology and other areas.
Oncology-Focused Pipeline with Multiple Clinical Candidates
Cabiralizumab (FPA008)
CSF-1R antibody

2L pancreatic cancer (Combination with Opdivo® and chemo)
1L maintenance Stand Up To Cancer and BMS supported trial (with Opdivo®)
Multiple tumor settings (Combination with Opdivo®)
Apexigen & BMS supported trial for APX005M (anti-CD40), cabira and Opdivo®
Bemarituzumab (FPA144)
FGFR2b antibody

FIGHT Phase 3 trial (with chemo) in gastric/GEJ cancer
FPA150
B7-H4 antibody
Multiple tumor settings
FPT155
CD80-Fc
Multiple tumor settings
BMS-986258
TIM-3 antibody

Phase 1/2 trial in multiple tumor settings
Multiple tumor settings
Multiple tumor settings